New drug AST-201 targets Hard-to-Treat cancers in first human trial
NCT ID NCT06687941
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a protein called GPC3. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug moves through the body and look for any signs it shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam, 13609, South Korea
-
National Cancer Center, Korea
RECRUITINGGoyang-si, Gyeonggi-do, 10408, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple belly press make liver cancer radiation more precise?
- Can a simple text message transform cancer care?